Shaping the future of Parkinson's care, together

Join the Remepy community and get updates, webinars, and news about our upcoming Phase III trial

I Want to Stay in Touch

Meet
‍HybridopaTM

An innovative Hybrid Drug being developed for Parkinson's disease. Hybridopa combines immediate-release levodopa/carbidopa - the most widely prescribed Parkinson's medication - with an app-delivered therapeutic protocol, aiming to improve motor & non-motor function as well as quality of life.

Phase IIa study results were published in Brain Communications:

9.7 improvementon the MDS-UPDRS scale vs. 1.95 in the control group

Phase III Trial

After encouraging Phase II results, we're preparing for a Phase III clinical trial in the US

Completed
Phase I Trial
Completed
Phase II Trial
+9.7 on MDS-UPDRS
NOW  2026
Phase III
Next:
Regulatory
Approval

Join Today

Join our newsletter to be the first to hear about it

I want to stay in touch

Content tailored for you

  • Useful
    Information

    Tips, tools, and insights about living with Parkinson's - body, mind, and relationships

  • Community

    Be part of a community of people living with Parkinson's, caregivers, and professionals who care

  • Research
    Updates

    News from Remepy’s advanced Hybridopa clinical trial - a new approach to Parkinson's care - and how you can take part

  • Webinars

    "Parkinson's, Real Talk" - conversations on topics that matter to you, with experts and community members sharing their lived experiences